The study randomized over 11,000 patients and the result showed that intravenous cangrelor cut the risk for periprocedural complications at all kinds of PCI compared with taking a pill of clopidogrel. Cangrelor's benefit of a 22% drop in a composite efficacy endpoint was driven by reductions in MI and stent thrombosis and was not associated with an increase in bleeding complications as they were prospectively defined. There were cautions, however, when bleeding complications were defined using other accepted criteria: Some kinds of bleeding were more common with cangrelor. These results clearly improve the management , complications and follow up of PCI.